L-Nutra Closes $47 Million in First Stage of Growth Investment Round
Summary
In partnership with 18 global university research centers, L-Nutra has developed the first Nutrition for Longevity pipeline, ProLon\xae aimed at enhancing healthy aging via cellular rejuvenation and improving metabolic health; and Nutrition as Medicine pipeline called L-Nutra Health aimed at enhancing patients chances of remission from diabetes, cancer, autoimmune and cardiovascular diseases. Led by Chairman and Chief Executive Officer Joseph Antoun, MD, PhD, L-Nutra has become the first nutri-technology company, touting more than 32 clinical trials and 200 worldwide patents. His personal investment in our company reinforces trust in our cutting-edge science and continued support of our global mission to increase longevity and healthspan across the globe," said Dr. Antoun. Stephane Bancel, CEO at Moderna added: "I have been thoroughly impressed by the science led by Dr. Valter Longo, and the products that L-Nutra has brought to market based on his research. L-Nutra has gathered 18 global universities to discover breakthrough nutrition formulations inspired by nature and tailored by Longevity Science to promote healthy aging and advance the development of nutri-therapeutic solutions for age-related diseases.